"Being honored by SC Magazine Awards Europe is a validation of ourleadership and innovation in delivering effective network security solutionsthat streamline security, network and virtual monitoring into one process, andhelp reduce the time, cost and complexity of network protection."StealthWatch now protects more than 40 million hosts worldwide and is deployedat hundreds of enterprise organizations across the financial services,manufacturing, federal government, healthcare, energy and higher educationsectors About LancopeLancope(R), Inc. is the provider of the StealthWatch(R) System, the mostwidely used network behavior analysis (NBA) solution that combines flow-basedanomaly detection and network performance monitoring. Delivering unifiedvisibility across physical and virtual networks, StealthWatch eliminatesnetwork blind spots and reduces total network and security management costs.StealthWatch streamlines security, network and virtual monitoring into oneprocess, reduces time and resources, and eliminates the costs and complexityassociated with non-integrated point products. Both OPSEC and CommonCriteria-certified, StealthWatch received the 2008 and 2007 Global ExcellenceAward in NBA. Defending the networks of Global 2000 organizations, academicinstitutions and government entities, StealthWatch protects hundreds ofenterprise customers worldwide, more than all direct competitors combined.Lancope also partners with fellow best-of-breed solution providers through itsTechnology Alliance Program, which includes Cisco Systems, Brocade, Blue Coat,VMware, IBM Tivoli, Check Point, TippingPoint, ArcSight and A10 Networks.
Lancope is a privately held, venture-backed company headquartered in Atlanta,Georgia. For more information, visit (C)2009 Lancope, Inc All rights reserved. Lancope, StealthWatch, and othertrademarks are registered or unregistered trademarks of Lancope, Inc. Allother trademarks are properties of their respective owners StealthWatch iscovered by U.S Patent Nos 7,290,283; 7,185,368; 7,475,426 and other U.S. andforeign patents pending.SOURCELancope, Inc.Alicia Beuke, Lancope Inc., +1-770-225-3128, . World stocks rose close to the previous day's near 4-month high onWednesday, helped by better-than-expected results from BNP Paribas and eurozone data showing firmer services business activity. Oil and other risky assets also pushed higher, while the low-yielding yenjumped after a source familiar with the result of a U.S.
banking stress testtold Reuters Bank of America (BAC.N) needed as much as $34 billion in extracapital Concerns about U.S. Paloma Pharmaceuticals Presents at the Association for Research in Vision andOphthalmology 2009 Meeting- Presentation describes Palomid 529 as a first-in-class Dual TORC1/TORC2complex inhibitor of the PI3K/Akt/mTOR pathway showing efficacy in retinalscarring caused by retinal detachment -JAMAICA PLAIN, Mass., May 6 /PRNewswire/ -- Paloma Pharmaceuticals, Inc.presented "Palomid 529, An Inhibitor of the Akt/mTOR Pathway ReducesPhotoreceptor Cell Death Following Experimental Retinal Detachment", today atthe annual meeting of the Association for Research in Vision and Ophthalmology2009 (ARVO 2009), This study, presented by Geoffrey P Lewis, Ph.D (alongwith G Luna, J Byun, E.A Chapin and S.K. Fisher) of the NeuroscienceResearch Institute and Molecular Cell & Developmental Biology Department ofthe University of California, Santa Barbara, CA. has been accepted forpublication in the journal Investigative Ophthalmology and Visual Science.Work from this study indicates that intravitreally administered Palomid 529slows photoreceptor cell death following retinal detachment in a seven dayrabbit study without obvious side effects to the retina. In some cases,blindness or other visual deficits may be permanent, and related to the deathof photoreceptor cells, the cells responsible for capturing light in theretina. We have presented data at ARVO demonstrating that a single intraocularinjection of Palomid 529, a drug originally designed as an anti-angiogenicagent, can significantly reduce this death in an animal model of retinaldetachment. In addition, we show that Palomid 529 also reduces the activationof glial cells and subsequently slows the formation of subretinal scar tissue,a condition that can prevent the regeneration of photoreceptors followingsuccessful retinal reattachment surgery.
Taken together these data suggestthat Palomid 529 may be neuroprotective to photoreceptors and reduce theincidence of subretinal fibrosis without obvious side effects to the retina,"says Dr. Lewis, study investigator.About Retinal DetachmentRetinal detachments can occur for a variety of reasons and, in general, can berepaired by retinal surgeons. Two potentially devastating complications ofretinal detachment, however, are proliferative vitreoretinopathy (PVR) andsubretinal fibrosis (scarring). When the retina becomes separated from theretinal pigment epithelium (RPE) because a tear or hole occurs in the retina,many cell types undergo proliferation and consequently have the potential toform retinal scars. When such cell types are present in the space between theretina and the RPE, subretinal fibrosis is the result and can prevent therecovery of photoreceptor cells even though the retina is reattached. Whensuch cells grow on the vitreal surface of the retina, they can formcontractile scar tissue leading to re-detachment of the retina. Together,these conditions are termed proliferative vitreoretinopathy (PVR).
Thus, agents capable of inhibiting the pathway are attractivetargets for therapeutic intervention.Central to the signalling pathway aretwo distinct protein complexes, one of which, TORC1, regulates cell growth byacting on the signal transduction protein S6K, while the other, TORC2,regulates cell survival through Akt. These complexes define therapamycin-sensitive and insensitive branches of the PI3K/Akt/mTOR pathway. Inhibitors of TORC2 may have beneficial effects without toxicity to normaltissues since loss of TORC2 in genetically altered mice does not appear toaffect normal tissue.TORC1 antagonists such as rapamycin (Sirolimus) haveshown activity in both animal models of ocular disease and in human clinicaltrials.The inhibition of both TORC1 and TORC2 should result in more completeinhibition of aberrant PI3K/Akt/mTOR signaling and are therefore of activeinterest for pharmaceutical development Palomid 529 is a first-in-class dualTORC1/TORC2 inhibitor About Paloma PharmaceuticalsPaloma Pharmaceuticals, Inc. For example, Woon determines the shiftin favor of policy change that occurred in 2008 as being about twice as largeas the one that occurred with Bill Clinton's election in 1992. Perhaps evenmore telling is the study's assessment that the shift favoring policy changeswas 40% larger in 2008 than in 1980 when Ronald Reagan defeated Jimmy Carter,and even twice as large than in 1932 when FDR was first elected."Modern political science's analytical theory and methods provide us with ascientific basis for confidently predicting that the promise of change willbecome a reality," concludes Woon. "Even if the tone in Washington remainsshrill and partisan, we can expect to observe a significant leftward shift inpolicies and therefore a clean break from the policymaking of the past 14years."The American Political Science Association (est.